Kyverna Therapeutics to Present at the 43rd Annual J. P. Morgan Healthcare Conference

Rhea-AI Summary

Kyverna Therapeutics (NASDAQ: KYTX), a clinical-stage biopharmaceutical company specializing in cell therapies for autoimmune diseases, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's CEO, Warner Biddle, will deliver a presentation outlining Kyverna's 2025 strategic priorities and key milestones on Monday, January 13, 2025, at 5:15 p.m. PST.

Interested parties can access a live audio webcast of the presentation through the Investors section of Kyverna's website at https://ir.kyvernatx.com/. The presentation recording will remain available on the website for 30 days after the conference.

News Market Reaction – KYTX

+1.31%

+1.31% Session move

In the trading session that priced this news, KYTX gained 1.31%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

EMERYVILLE, Calif., Jan. 6, 2025 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna, NASDAQ: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, announced that the Company will participate at the 43rd Annual J.P. Morgan Healthcare Conference. Warner Biddle, Chief Executive Officer of Kyverna, will present its 2025 strategic priorities and key milestones during a presentation on Monday, January 13, 2025, at 5:15 p.m. PST.

A live audio webcast of the presentation may be accessed via the Investors section of the Kyverna website at https://ir.kyvernatx.com/. A replay of the webcast will be available on the website for 30 days following the conference. 

About Kyverna Therapeutics 
Kyverna Therapeutics, Inc. (Nasdaq: KYTX) is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. Our lead CAR T-cell therapy candidate, KYV-101, is advancing through clinical development with sponsored clinical trials across two broad areas of autoimmune disease: rheumatology and neurology, including Phase 2 trials for stiff-person syndrome, multiple sclerosis and myasthenia gravis, a Phase 1/2 trial for systemic sclerosis, and two ongoing multi-center Phase 1/2 trials in the United States and Germany for patients with lupus nephritis. Kyverna's pipeline includes next-generation CAR T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.

For more information, please visit https://kyvernatx.com. 

Forward-Looking Statements 
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." The words, without limitation, "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Forward-looking statements in this press release include, without limitation, those related to: Kyverna's participation at the 43rd Annual J.P. Morgan Healthcare Conference and the expected discussion of Kyverna's strategic priorities and key anticipated milestones and Kyverna's ongoing clinical trials. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties related to market conditions, and other factors discussed in the "Risk Factors" section of Kyverna's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q that Kyverna has filed or may subsequently file with the U.S. Securities and Exchange Commission. Any forward-looking statements contained in this press release are based on the current expectations of Kyverna's management team and speak only as of the date hereof, and Kyverna specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.  

Contact:
Investors: InvestorRelations@kyvernatx.com 
Media: media@kyvernatx.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/kyverna-therapeutics-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-302343449.html

SOURCE Kyverna Therapeutics

FAQ

When is Kyverna Therapeutics (KYTX) presenting at the 2025 J.P. Morgan Healthcare Conference?

Kyverna Therapeutics will present on Monday, January 13, 2025, at 5:15 p.m. PST at the 43rd Annual J.P. Morgan Healthcare Conference.

How can investors access Kyverna's (KYTX) J.P. Morgan Healthcare Conference presentation?

Investors can access the live audio webcast through the Investors section of Kyverna's website at https://ir.kyvernatx.com/. A replay will be available for 30 days following the conference.

What will be discussed in Kyverna's (KYTX) presentation at the J.P. Morgan Healthcare Conference?

CEO Warner Biddle will present Kyverna's 2025 strategic priorities and key milestones during the presentation.

How long will Kyverna's (KYTX) J.P. Morgan Healthcare Conference presentation be available for replay?

The presentation webcast replay will be available on Kyverna's website for 30 days following the conference.